JPET

Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
 QUICK SEARCH:   [advanced]


     


This Article
Right arrow Full Text
Right arrow Full Text (PDF)
Right arrow Submit a response
Right arrow Alert me when this article is cited
Right arrow Alert me when eLetters are posted
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Matsumoto, M.
Right arrow Articles by Yoshioka, M.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Matsumoto, M.
Right arrow Articles by Yoshioka, M.

Vol. 296, Issue 3, 676-682, March 2001

Evidence for Involvement of Central 5-HT4 Receptors in Cholinergic Function Associated with Cognitive Processes: Behavioral, Electrophysiological, and Neurochemical Studies

Machiko Matsumoto, Hiroko Togashi, Kiyoshi Mori, Ken-ichi Ueno, Satoshi Ohashi, Taku Kojima and Mitsuhiro Yoshioka

Departments of Pharmacology (M.M., H.T., K.M., K.-i.U., S.O., M.Y.) and Anesthesiology (T.K.), Hokkaido University School of Medicine, Sapporo, Japan

The possible involvement of 5-HT4 receptors in cognitive function was investigated with a view toward modulating the cholinergic neuronal system. For this purpose, behavioral, electrophysiological, and neurochemical studies were performed in rats. The behavioral study, using a passive avoidance test, demonstrated that the 5-HT4 receptor agonist SC 53116 (10 µg/rat i.c.v.) had an ameliorative effect on the muscarinic receptor antagonist scopolamine-induced (1 mg/kg i.p.) impairment of learning. The electrophysiological study showed that SC 53116 (1 and 10 µg/rat i.c.v.) enhanced the population spike amplitude in the hippocampal CA1 field evoked by Schaffer collateral stimulation. SC 53116 (10 µg/rat i.c.v.) also augmented the tetanus-induced long-term potentiation (LTP). This augmented LTP was blocked not only by the selective 5-HT4 receptor antagonist GR 113808 (20 µg/rat i.c.v.) but also by scopolamine (1 mg/kg i.p.). These findings suggest that the functional interaction between the serotonergic system mediated via 5-HT4 receptors and the cholinergic system associated with cognitive processes exists in vivo. This possibility was further strengthened by neurochemical study using in vivo microdialysis; local administration of SC 53116 (10 and 100 µM) concentration-dependently enhanced the extracellular levels of acetylcholine (ACh) in the hippocampus. SC 53116-induced (10 µM) facilitation of ACh release was prevented by coperfusion of GR 113808 (10 µM). Taken together, the present findings obtained by these different approaches indicate the possibility that the 5-HT4 receptors are involved in cognitive impairment induced by the cholinergic neuronal system.


0022-3565/01/2963-0676$03.00/0
THE JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS
Copyright © 2001 by The American Society for Pharmacology and Experimental Therapeutics



This article has been cited by other articles:


Home page
Cereb CortexHome page
A. Kemp and D. Manahan-Vaughan
The 5-Hydroxytryptamine4 Receptor Exhibits Frequency-dependent Properties in Synaptic Plasticity and Behavioural Metaplasticity in the Hippocampal CA1 Region In vivo
Cereb Cortex, July 1, 2005; 15(7): 1037 - 1043.
[Abstract] [Full Text] [PDF]


Home page
J. Neurosci.Home page
A. C. Shakesby, R. Anwyl, and M. J. Rowan
Overcoming the Effects of Stress on Synaptic Plasticity in the Intact Hippocampus: Rapid Actions of Serotonergic and Antidepressant Agents
J. Neurosci., May 1, 2002; 22(9): 3638 - 3644.
[Abstract] [Full Text] [PDF]




Home Help [Feedback] [For Subscribers] [Archive] [Search] [Contents]
All ASPET Journals Molecular Pharmacology Pharmacological Reviews
 Molecular Interventions Drug Metabolism and Disposition

Copyright © 2001 by the American Society for Pharmacology and Experimental Therapeutics.